NSE: INDGN | BSE: 544172

Mid-range Performer

Download real time

567.35 -2.35 (-0.41%)

Near 52W High of ₹596.80

474.4K NSE+BSE Volume

NSE 27 Aug, 2026 3:31 PM (IST)

13,668.2

Market Cap

High in industry

Beta 1Year

Low volatility

Indegene Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDGN, BSE:544172 Indegene Ltd.

Search Inside the pdf :

Indegene Ltd.

31 Jul 2026

567.35

-0.41%

Performance in line with expectations; FY27 expected to be better than FY26

Neutral: Indegene Ltd.

Target

Motilal Oswal

Indegene’s 1QFY27 revenue rose 2.5% QoQ and 26.5% YoY to USD113m (in line with our estimate), while INR revenue grew 6.0% QoQ and 39.7% YoY to INR10.6b (MOFSL est: INR10.4b).

Indegene has gained 15.16% in the last 1 Month

Indegene Ltd.

29 Jul 2026

567.35

-0.41%

market depends on pharma commercialization, medical affairs and regulatory outsourcing with an estimation at over USD 40bn by 2033, yet Indegene's FY26 revenue represents well under 0.2% of this opportunity. Rising drug development costs, patent cliffs, and increasing outsourcing...

Indegene has gained 15.16% in the last 1 Month

Indegene Ltd.

02 May 2026

567.35

-0.41%

Robust growth with improving life sciences demand outlook

Buy: Indegene Ltd.

ICICI Securities Limited

Indegene showed robust revenue growth performance with broad-based traction across ECS/EMS. Issues in top client seem to have abated for now.

Indegene Ltd. has an average target of 603.33 from 3 brokers.

Indegene Ltd.

02 May 2026

567.35

-0.41%

Performance in line; FY27 likely to be better than FY26

Neutral: Indegene Ltd.

Target

Motilal Oswal

Indegene’s 4QFY26 revenue rose to 6.5% QoQ to INR10b (in line with our estimate), while Ex-BioPharm revenue growth stood at 5.6%.

Indegene Ltd. has an average target of 603.33 from 3 brokers.

Indegene Ltd.

31 Jan 2026

567.35

-0.41%

Acquisition drives growth with steady organic performance

Neutral: Indegene Ltd.

Motilal Oswal

Indegene’s 3QFY26 USD revenue rose 15.1% QoQ, aided by the BioPharm acquisition, while organic USD revenue growth stood at 4% QoQ (below our estimate).

Indegene Ltd. is trading above all available SMAs

Indegene Ltd.

10 Jul 2024

567.35

-0.41%

Indegene Limited - Revolutionizing Life Sciences' Marketing Way

Buy: Indegene Ltd.

Monarch Networth Capital Limited

Indegene Ltd. is trading above all available SMAs

Indegene Ltd.

03 May 2024

567.35

-0.41%

IPO Note - Indegene Limited 06052024

IPO Note: Indegene Ltd.

HDFC Securities

IPO Note - Indegene Limited Indegene Limited (IL) provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products